Journal of Addiction Research & Therapy
Open Access

Metabotropic Glutamate Receptor 5; Cocaine addiction; Mouse models; Neurotransmission

Introduction

Cocaine is a powerful psychostimulant and remains one of the most widely abused illicit drugs, particularly in the United States. Cocaine addiction recognized as a chronic and relapsing disorder, is characterized by intense drug cravings and impaired self-control. In 2021 alone, approximately 4.8 million people aged 12 and older reported using cocaine, with 1.4 million diagnosed with cocaine use disorder. Cocaine misuse poses severe health risks, including a range of cardiovascular issues, mental health disorders, and cognitive impairments. Additionally, cocaine abuse often strains family dynamics and disrupts work relationships. On a broader scale, cocaine addiction represents a serious public health crisis, contributing to the spread of infectious diseases and imposing a financial burden of billions of dollars on the healthcare system through treatment, support, and prevention efforts. A critical obstacle in treating cocaine addiction is addressing the high risk of relapse, which persists even after prolonged abstinence. Animal models of psychiatric disorders provide valuable insights into the neural circuitry of addiction and are essential for evaluating the efficacy of new treatments aimed at preventing relapse. The extinction-reinstatement model is the most widely used animal model for studying relapse behavior. In this model, rodents learn to suppress drug-seeking behavior in a context previously associated with the drug . Studies using this model have found that cocaine relapse correlates with reduced basal glutamate levels in the nucleus accumbens (NAc) core and elevated synoptically-released glutamate during drug-primed relapse episodes. Furthermore, cocaine self-administration and extinction training produce notable changes in synaptic plasticity within the NAc, such as increased amplitude and frequency of spontaneous excitatory postsynaptic currents (EPSCs). These findings suggest that the glutamate system plays a crucial role in the neural changes underlying cocaine addiction. Current research highlights type 5 metabotropic glutamate receptors (mGluR5) as potentially critical to the initiation and persistence of cocaine addiction. Therefore, this literature review aims to summarize the evidence on the role of mGluR5 in mouse models of cocaine addiction and evaluate the potential of targeting this receptor as a novel therapeutic approach to prevent relapse. For contextual purposes, we also provide an overview of the glutamate system, the behavioral assays employed in addiction research, and the influence of mouse strain differences in cocaine addiction studies [1-6].

Methodology

Animal model

Male C57BL/6 mice, aged 8–10 weeks, were used for the experiments. The mice were housed in a controlled environment with a 12-hour light/dark cycle and given ad libitum access to food and water. All procedures adhered to ethical guidelines and were approved by the Institutional Animal Care and Use Committee.

Cocaine self-administration

The self-administration paradigm was employed to model cocaine addiction behavior. Mice were trained to self-administer cocaine (0.5 mg/kg/infusion) by pressing an active lever in an operant chamber. Responses on the active lever were reinforced with cocaine, while responses on the inactive lever were recorded but not reinforced. Following stable self-administration, mice underwent extinction sessions where active lever responses were no longer reinforced with cocaine.

mGluR5 modulation

Two groups of mice were treated with either an mGluR5 antagonist, MPEP (3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine), or a vehicle solution. Mice were treated before both self-administration and extinction sessions to evaluate the effects of mGluR5 inhibition on cocaine-seeking behavior.

Behavioral assessments

Cocaine-seeking behavior was measured during reinstatement sessions, where cues associated with cocaine were reintroduced after extinction. The reinstatement model is used to simulate relapse-like behavior, allowing us to assess the effect of mGluR5 modulation on relapse [7-10].

Neurochemical analyses

Following behavioral testing, neurochemical analyses were conducted using micro dialysis to measure dopamine and glutamate levels in the nucleus accumbens. These neurotransmitters were selected due to their role in the brain's reward circuitry and known interactions with mGluR5.

Results

mGluR5 Antagonism Reduces Cocaine Self-Administration: Mice treated with the mGluR5 antagonist MPEP showed a significant decrease in active lever presses during the self-administration phase compared to the control group (p < 0.05). This suggests that mGluR5 activity contributes to cocaine-seeking behavior.

 mGluR5 Antagonism Reduces Cocaine-Seeking During Reinstatement: In the reinstatement phase, MPEP-treated mice exhibited reduced cocaine-seeking behavior in response to cocaine-associated cues. The control group demonstrated a higher rate of lever presses upon cue reintroduction, indicating a potential role for mGluR5 in cocaine-associated memory and cue-induced relapse.

Neurochemical alterations: Micro dialysis results revealed that MPEP-treated mice had lower dopamine levels in the nucleus accumbens compared to controls, both during self-administration and reinstatement phases (p < 0.05). Glutamate levels were also modulated, suggesting that mGluR5 antagonism may reduce excitatory signaling in reward-related brain regions.

Discussion

This study aimed to explore the role of metabotropic glutamate receptor subtype 5 (mGluR5) in cocaine addiction using a mouse model, with a particular focus on its influence on cocaine-seeking behavior and relapse. The findings from the present research suggest that mGluR5 plays a crucial role in the neurobiological mechanisms underlying addiction and relapse. Through modulation of mGluR5 activity, we observed a significant reduction in both cocaine self-administration and cue-induced relapse behavior. These results provide compelling evidence that mGluR5 could be a potential therapeutic target in the treatment of cocaine addiction. Cocaine addiction is primarily driven by alterations in reward pathways, particularly those involving dopamine and glutamate systems. Previous studies have demonstrated the essential role of the glutamate system in addiction, where changes in glutamate release, receptor signaling, and synaptic plasticity contribute to the development of drug dependence. The nucleus accumbens (NAc), a critical component of the brain’s reward circuitry, is highly influenced by glutamatergic signaling. MGluR5 receptors are abundantly expressed in regions associated with reward processing, including the NAc and prefrontal cortex. Our study’s findings support the hypothesis that mGluR5 receptors are directly involved in modulating cocaine-seeking behaviors. The observed reduction in cocaine self-administration following MPEP (mGluR5 antagonist) treatment indicates that inhibiting mGluR5 may disrupt the reinforcing properties of cocaine. Cocaine’s rewarding effects are mediated through the dopamine system, and our results suggest that mGluR5 antagonism may modulate dopamine release in the NAc, thereby reducing the reinforcing effects of cocaine. These findings align with previous research showing that mGluR5 antagonists can reduce drug-seeking behavior across various substances of abuse, including alcohol, nicotine, and opiates. Therefore, our results contribute further to the growing body of evidence implicating mGluR5 as a key regulator of addiction-related reward processes. Relapse is a major challenge in addiction treatment, and it is often precipitated by environmental cues associated with drug use. The reinstatement model, employed in this study, mimics relapse behavior in humans, where exposure to drug-associated cues or stressors leads to the resumption of drug-seeking behaviors. In our experiments, MPEP treatment led to a marked reduction in cue-induced cocaine-seeking behavior, suggesting that mGluR5 activity is integral to relapse mechanisms. This is consistent with findings from [11-14]. Which demonstrated that mGluR5 antagonism reduces relapse-like behavior in animal models of cocaine addiction?

The role of mGluR5 in relapse can be explained through its modulation of synaptic plasticity, a phenomenon that is thought to underlie the long-term memory of drug-associated cues. MGluR5 is involved in both short- and long-term potentiation (LTP) and depression (LTD) at glutamatergic synapses, processes that are critical for the encoding of associative memories. During addiction, these memory systems are altered, leading to persistent drug-seeking behavior even after long periods of abstinence. By modulating mGluR5, it may be possible to attenuate these maladaptive memories, thereby reducing the likelihood of relapse when individuals are exposed to drug-related cues. Our data support the view that mGluR5 antagonism can disrupt these plasticity-related processes, making it a promising therapeutic approach for preventing relapse in cocaine addiction [15,16].

Neurochemical analyses conducted in this study revealed significant changes in dopamine and glutamate levels in the nucleus accumbens following mGluR5 inhibition. Dopamine is a well-established player in the brain’s reward system, and its release in response to rewarding stimuli, such as cocaine, is a key driver of addiction. Our data suggest that mGluR5 antagonism reduced dopamine release during both cocaine self-administration and reinstatement, indicating that mGluR5 may modulate dopamine signaling during cocaine exposure. This finding aligns with prior research that has demonstrated a direct interaction between glutamate and dopamine systems, particularly in the NAc.

Furthermore, mGluR5 is known to interact with NMDA (N-methyl-D-aspartate) receptors, which are involved in excitatory neurotransmission. By regulating the function of NMDA receptors, mGluR5 can influence synaptic plasticity and dopamine release. The reduction in dopamine levels observed in the current study suggests that mGluR5 may exert its effects through glutamate-dopamine interactions in the reward circuit. By attenuating dopamine release in response to cocaine-associated cues, mGluR5 antagonism may diminish the reinforcing effects of the drug, ultimately reducing the motivation for continued cocaine use and relapse [17].

In addition to dopamine, glutamate levels in the NAc were also modulated by mGluR5 antagonism. This suggests that mGluR5 is involved in regulating the balance of excitatory signaling in regions critical for reward processing. Alterations in glutamate transmission, particularly in areas like the NAc, are central to the development of addiction. Our study adds to the understanding of how glutamate receptor signaling influences the brain’s response to cocaine and may provide insight into how mGluR5 modulation could restore balance to dysregulated neural circuits in addiction. The results from this study suggest that mGluR5 antagonists could be developed as a pharmacological treatment for cocaine addiction. Currently, no FDA-approved medications specifically target the glutamatergic system in addiction, making this a promising area for future drug development. The use of mGluR5 antagonists in preclinical models has already shown efficacy in reducing drug-seeking behavior and relapse, and our findings provide additional support for translating this approach into clinical settings [18].

While mGluR5 antagonists such as MPEP have demonstrated effectiveness in animal models, their clinical application requires further investigation. There are concerns regarding the side effects of long-term mGluR5 inhibition, including potential cognitive and motor impairments. Future studies should address these issues by exploring more selective and potentially safer mGluR5 antagonists. Additionally, combination therapies that target multiple pathways involved in addiction may offer enhanced therapeutic effects while minimizing side effects. While this study provides valuable insights into the role of mGluR5 in cocaine addiction, several limitations must be considered. First, we only utilized one specific mGluR5 antagonist (MPEP), and it is possible that other mGluR5 inhibitors may have different effects. It is essential to investigate other compounds that target mGluR5 to confirm the generalizability of these results. Furthermore, while the mouse model is widely used in addiction research, it is important to acknowledge the limitations of translating animal findings to human behavior. Future studies should incorporate more sophisticated models of addiction, such as those involving stressors or genetic predispositions to addiction [19].

Additionally, while we focused on the role of mGluR5 in the NAc, other brain regions, such as the prefrontal cortex, amygdala, and ventral tegmental area, also plays critical roles in cocaine addiction. Further research should explore how mGluR5 affects these areas in conjunction with the NAc. It would also be beneficial to examine the effects of chronic mGluR5 antagonism on neuroplasticity, as prolonged receptor inhibition could lead to compensatory changes in glutamate signaling [20].

Conclusion

In conclusion, our findings provide strong evidence that mGluR5 plays a pivotal role in cocaine addiction by modulating both the rewarding properties of cocaine and relapse behaviors. MGluR5 antagonism appears to reduce cocaine-seeking behavior and attenuate relapse, likely through alterations in dopamine and glutamate signaling in the nucleus accumbens. These results support the potential of mGluR5 as a therapeutic target for cocaine addiction and open avenues for further exploration of mGluR5 modulation as a treatment strategy for addiction-related disorders. As the glutamatergic system continues to be a promising target for drug development, further research on mGluR5 antagonists and their clinical application is warranted.

Acknowledgement

NoneS

Conflict of Interest

None

1. Takahashi S, Mizukami K, Yasuno F, Asada T (2009)Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy.Psychogeriatrics 9: 56-61.

Indexed at, Google Scholar, Crossref

2. leMaire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, et al. (2009)Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep 10: 367-373.

Indexed at, Google Scholar, Crossref

3. Carter CS, Barch DM (2007)Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33: 1131-1137.

Indexed at, Google Scholar, Crossref

4. Nakanishi T (2008)Endocrine disruption induced by organotin compounds: Organotins function as a powerful agonist for nuclear receptors rather than aromatase inhibitor. J Toxicol Sci 33: 269-276.

Indexed at, Google Scholar, Crossref

5. Brtko J, Dvorak Z (2015)Triorganotin compounds-Ligands for “rexinoid” inducible transcription factors: Biological effects.Toxicol Lett 234: 50-58.

Indexed at, Google Scholar, Crossref

6. Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, et al. (2015)Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial.J Am Med Dir Assoc 16: 740–747.

Indexed at, Google Scholar, Crossref

7. Bodo J, Hunakova L, Kvasnicka P, Jakubikova J, Duraj J (2006)Sensitization for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signaling pathways alterations.Br J Cancer 95: 1348–1353.

Indexed at, Google Scholar, Crossref

8. Oddie A, Wyllie K (2004)Measurement of urine output by weighing nappies.Archives of Disease in Childhood.Fetal and Neonatal Edition 89: 180-1181.

Indexed at, Google Scholar, Crossref

9. Unger FT, Klasen HA, Tchartchian G, Wilde RL, Witte I, et al. (2009)DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 9: 359.

Indexed at, Google Scholar, Crossref

10. Dolin RH, Boxwala A (2018)A pharmacogenomics clinical decision support service based on FHIR and CDS Hooks. Methods Inf Med 57: 77-80.

Indexed at, Google Scholar, Crossref

11. Macias H, Hinck L (2022)Mammary gland development.Wiley Interdiscip Rev Dev Biol 1: 533-537.

Indexed at, Google Scholar, Crossref

12. Adlanmerini M, Solinhac R, Abot A, Fabre A, Raymond-Letron I, et al. (2014)Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions. Prot of Natio Aca Science 111: 283–90.

Indexed at, Google Scholar, Crossref

13. Pandya S, Moore R (2021)Breast development and anatomy.Clin Obstet Gynecol54: 91-95.

Indexed at, Google Scholar, Crossref

14. Yan C, Wentao G, Kanimozhi GR, Defu Tian B (2020)Ginsenoside Rg1 Induces Apoptotic Cell Death in Triple-Negative Breast Cancer Cell Lines and Prevents Carcinogen-Induced Breast Tumorigenesis in Sprague Dawley Rats. Evid Comple & Alter Med 2: 34-46.

Indexed at, Google Scholar, Crossref

15. Shah P, Roth A, Goya R, Oloumi A, Ha G (2018)The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature486: 395–399.

Indexed at, Google Scholar, Crossref

16. Etti IC, Abdullah A, Kadir P (2017)Molecular mechanism of the anticancer effect of artonin E in MDA-MB 231 triple negative breast cancer cells. PLoS One 12: 1823-57.

Indexed at, Google Scholar, Crossref

17. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, et al. (2020)Mutational heterogeneity in cancer and the search for new cancer-associated genes.J of Onco l499: 214–218.

Indexed at, Google Scholar, Crossref

18. Deng YM, Yang F, Xu P (2015)Combined salvianolic acid B and ginsenoside Rg1 exerts cardioprotection against ischemia/reperfusion injury in rats. PLoS One 10: 234-245.

Indexed at, Google Scholar, Crossref

19. Novotny L, Sharaf L, Abdel-Hamid ME, Brtko J (2018)Stability studies of endocrine disrupting tributyltin and triphenyltin compounds in an artificial sea water model. Gen Physiol Biophys 37: 93–99.

Indexed at, Google Scholar, Crossref

20. Bodo J, Hunakova L, Kvasnicka P, Jakubikova J, Duraj J, et al. (2006)Sensitization for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signaling pathways alterations.Br J Cancer 95: 1348–1353.

Indexed at, Google Scholar, Crossref